![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
AtomVie Global Radiopharma has signed a lease agreement with Panattoni Development Company in Hamilton, Ontario, Canada, for its new state-of-the-art facility. AtomVie’s new facility will be dedicated to high volume clinical and commercial GMP manufacturing and worldwide distribution of radiotherapeutics, an innovative, high-growth class of drugs for the treatment of cancer patients.
Currently located on the McMaster University campus, AtomVie operates a contract development and manufacturing organization (CDMO) facility that is home for more than 10 international radiopharmaceutical GMP manufacturing programs. The new facility of 64,000 sq. ft., expected to be commissioned in 2024, will increase production capacity more than 10 times, allowing the expansion of its clinical and commercial operations to meet the needs of the rapidly expanding radiopharmaceutical market.
Hallmarks of the new facility include cleanrooms and laboratories to sustain over 18 production lines and space for dedicated, high-volume commercial manufacturing. The facility is located in proximity of the Toronto Pearson International Airport, the John C. Munro Hamilton International Airport and the U.S. border.
“AtomVie celebrates yet another milestone by beginning a buildout that will increase our capacity more than ten-fold,” said Bruno Paquin, CEO of AtomVie Global Radiopharma. “We are thrilled to continue being part of the Hamilton radiopharmaceutical ecosystem and by partnering with Panattoni, we were able to choose our new facility’s home to meet clinical and commercial supply needs for radiotherapeutics, resulting in patients receiving much-needed therapies.”
Kevin McNeill, partner at Avego and AtomVie’s chair of the board of directors, said, “AtomVie’s new facility will provide much-needed capacity for the high-growth global radiopharmaceutical market. We are pleased to be able to meet the expanding needs of our clients and patients.”
New site in Canada will be dedicated to high volume clinical and commercial GMP manufacturing and worldwide distribution of radiotherapeutics.
